Giuseppe Curigliano, MD, PhD, head of the Division of Early Drug Development at European Institute of Oncology, in Milan, Italy, discusses the emergence of immunotherapy in breast cancer.

The combination of checkpoint inhibitors and chemotherapy is showing the most promise, says Curigliano, specifically in certain patients with triple-negative breast cancer (TNBC). Though this combination is showing results in some patients, Curigliano adds that it is not for all patients with breast cancer, or even all patients with TNBC.

Focus needs to be put on patient selection to optimize immunotherapy as a treatment in this disease. This should start with individual assessment of tumor-infiltrating lymphocytes in patients with TNBC, according to Curigliano.

View more from the St. Gallen's Breast Cancer Conference

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Breast Cancer

ELI-22-OSD1261 - /clinical/colorectal-cancer

 Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr. Curigliano Discusses Immunotherapy in Breast Cancer